Literature DB >> 30018726

Impact of sentinel lymph node biopsy in newly diagnosed invasive breast cancer patients with suspicious node: a comparative accuracy survey of fine-needle aspiration biopsy versus core-needle biopsy.

Adheesh Bhandari1, Erjie Xia1, Yinghao Wang1, Namita Sindan2, Ranjan Kc3, Yaoyao Guan1, Yueh-Lung Lin4, Xiaoshang Wang5, Xiaohua Zhang1, Ouchen Wang1.   

Abstract

Comparing diagnostic accuracy study between ultrasonography (US) guided fine-needle aspiration biopsy (FNAB) and core-needle biopsy (CNB) of the Sentinel lymph nodes (SLNs) in newly diagnosed invasive breast cancer patients. We selected 289 newly diagnosed invasive breast cancer patients from June 2015 to July 2017. Ultrasound (US) guided fine-needle aspiration cytology (FNA) and core-needle biopsy (CNB) was performed to identify patients with suspicious sentinel lymph node (SLN). Patients with a cortical thickness > 2 mm or atypical morphological characteristics were recommended FNA and CNB. Axillary lymph node dissection (ALND) was applied to patients with biopsy-proven metastasis, and sentinel lymph node biopsy (SLNB) was applied to FNA or CNB negative patients. ALND was also performed when SNB is positive. Out of 289 patients, only 131 patients met final study criteria. Lymph node status was evaluated by FNA, CNB, SLND, and ALND. Among 131 patients, 45 were deemed positive for metastasis and 86 were determined to be negative with CNB, whereas 38 were deemed positive for metastasis and 93 were determined to be negative by using FNAB. CNB was used to correctly identify seven axillae as positive for metastasis that were deemed negative by using FNAB. There were no positive FNAB results in axillae that were negative for metastasis with CNB. All patients underwent SLNB and those with biopsy-proved axillary metastases were assigned directly to ALND as the primary staging procedure. The final histopathologic assessment indicated that 50 (38.2%) of the 131 axillae studied had axillary LN metastases. Axillary US-guided CNB was used to correctly identify 45 (90.0%) of the 50 LN-positive axillae, whereas axillary US-guided FNAB was used to correctly identify 38 (76.0%, P < 0. 001). There were no false-positive results. CNB netted 5 false-negative results, and FNAB resulted in 12. There was significantly different accuracy between different diagnostic tools. In our study, we demonstrated that CNB is a more reliable approach than FNA for the preoperative diagnosis of SLN metastasis.

Entities:  

Keywords:  Fine-needle aspiration; breast cancer; carbon nanoparticles suspension injection; combined approach; core needle biopsy; radioisotope suspension injection; sentinel lymph node

Year:  2018        PMID: 30018726      PMCID: PMC6038083     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  75 in total

1.  Sentinel lymphadenectomy for breast cancer: experience with 180 consecutive patients: efficacy of filtered technetium 99m sulphur colloid with overnight migration time.

Authors:  D J Winchester; S F Sener; D P Winchester; R M Perlman; R A Goldschmidt; G Motykie; C H Martz; S L Rabbitt; D Brenin; M A Stull; J M Moulthrop
Journal:  J Am Coll Surg       Date:  1999-06       Impact factor: 6.113

2.  Initial axillary staging of breast cancer using ultrasound-guided fine needle aspiration: a liquid-based cytology study.

Authors:  A Schiettecatte; C Bourgain; C Breucq; N Buls; V De Wilde; J de Mey
Journal:  Cytopathology       Date:  2011-02       Impact factor: 2.073

Review 3.  Combustion-derived nanoparticles: mechanisms of pulmonary toxicity.

Authors:  Kelly BéruBé; Dominique Balharry; Keith Sexton; Lata Koshy; Tim Jones
Journal:  Clin Exp Pharmacol Physiol       Date:  2007-10       Impact factor: 2.557

4.  OpenEpi: a web-based epidemiologic and statistical calculator for public health.

Authors:  Kevin M Sullivan; Andrew Dean; Minn Minn Soe
Journal:  Public Health Rep       Date:  2009 May-Jun       Impact factor: 2.792

5.  Management of axillary lymph node metastasis in breast cancer: making progress.

Authors:  Grant Walter Carlson; William C Wood
Journal:  JAMA       Date:  2011-02-09       Impact factor: 56.272

6.  Lymphatic mapping and sentinel lymph node biopsy in patients with breast cancer.

Authors:  C E Cox; S S Bass; C R McCann; N N Ku; C Berman; K Durand; M Bolano; J Wang; E Peltz; S Cox; C Salud; D S Reintgen; G H Lyman
Journal:  Annu Rev Med       Date:  2000       Impact factor: 13.739

7.  Differentiation of benign from malignant superficial lymphadenopathy: the role of high-resolution US.

Authors:  P Vassallo; K Wernecke; N Roos; P E Peters
Journal:  Radiology       Date:  1992-04       Impact factor: 11.105

8.  Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma.

Authors:  J E Gershenwald; M I Colome; J E Lee; P F Mansfield; C Tseng; J J Lee; C M Balch; M I Ross
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

9.  Sentinel lymph node detection using methylene blue in patients with early stage cervical cancer.

Authors:  Song-Hua Yuan; Ying Xiong; Mei Wei; Xiao-Jian Yan; Hui-Zhong Zhang; Yi-Xin Zeng; Li-Zhi Liang
Journal:  Gynecol Oncol       Date:  2007-05-11       Impact factor: 5.482

10.  Gamma probe-guided sentinel node biopsy--optimal timing for injection.

Authors:  S Schneebaum; J Stadler; M Cohen; D Yaniv; J Baron; Y Skornick
Journal:  Eur J Surg Oncol       Date:  1998-12       Impact factor: 4.424

View more
  2 in total

1.  Preoperative Ultrasound-guided Core Biopsy of Axillary Nodes for Staging of Clinically Negative Axilla in Breast Cancer Patients - A Pilot Study.

Authors:  Shaista Afzal; Imrana Masroor; Asma Munir; Romana Idress; Poonum Khan; Shaista Khan
Journal:  Cureus       Date:  2020-01-21

2.  Comparative study of core needle biopsy and fine needle aspiration in the treatment of metastatic lymph nodes guided by contrast-enhanced ultrasound.

Authors:  Wei-Na Mu; Jian-Heng Li; Ying Liu; Hui-Qing Liang; Xin Liu
Journal:  Pak J Med Sci       Date:  2022 Jul-Aug       Impact factor: 2.340

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.